Mrs Isabelle Wilson
Whitehall II Project Manager
Ms Stephanie Smith
Study & Data Co-ordinator
Tel: 0800 068 1562 or
020 7679 5621
Data sharing enquiries:
Dr Aida Sanchez
By combining existing 28 years of data on social inequalities and chronic disease with new clinical measures of cognitive function, mental disorders and physical functioning, Whitehall II has become a world-class, interdisciplinary study of ageing.
Ageing is not characterised by universal decline. Rather variations in the speed of ageing result in people of the same age becoming increasingly dissimilar in terms of cognitive capability, mental and physical health and functioning over time. Understanding the causes of this age-related individual heterogeneity and its distribution by social group is the core focus of our current work.
In addition to providing insights into individual and social differences in the development of frailty, disability, dependence, and dementia, our work enables the determination of optimal time windows and targets for interventions that maximize the potential for healthy-ageing and independent living.
Our recent research highlights are:
The unique feature of the Whitehall II cognitive data is assessment starting at age 45, allowing us to study the social, behavioural and biological determinants of heterogeneity in cognitive decline, starting in midlife. Continued follow-up of the cohort will allow us to assess the outcomes of cognitive impairment and dementia.
- Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife. Singh-Manoux A, Dugravot A, Brunner E, Kumari M, Shipley M, Elbaz A, Kivimaki M.Neurology. 2014; 83: 486-93.
- Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Tuligenga RH, Dugravot A, Tabák AG, Elbaz A, Brunner EJ, Kivimäki M, Singh-Manoux A. Lancet Diabetes Endocrinol. 2014; 2: 228-35.
- Alcohol consumption and cognitive decline in early old age. Sabia S, Elbaz A, Britton A, Bell S, Dugravot A, Shipley M, Kivimaki M, Singh-Manoux A.Neurology. 2014; 82: 332-9.
- Midlife stroke risk and cognitive decline: a 10-year follow-up of the Whitehall II cohort study. Kaffashian S, Dugravot A, Brunner EJ, Sabia S, Ankri J, Kivimäki M, Singh-Manoux A. Alzheimers Dement. 2013; 9: 572-9.
- Impact of smoking on cognitive decline in early old age: the Whitehall II cohort study. Sabia S, Elbaz A, Dugravot A, Head J, Shipley M, Hagger-Johnson G, Kivimaki M, Singh-Manoux A. Arch Gen Psychiatry. 2012; 69: 627-35.
- Timing of onset of cognitive decline: results from Whitehall II prospective cohort study. Singh-Manoux A, Kivimaki M, Glymour MM, Elbaz A, Berr C, Ebmeier KP, Ferrie JE, Dugravot A. BMJ. 2012; 344:d7622.
- Predictive utility of the Framingham general cardiovascular disease risk profile for cognitive function: evidence from the Whitehall II study. Kaffashian S, Dugravot A, Nabi H, Batty GD, Brunner E, Kivimäki M, Singh-Manoux. A. Eur Heart J. 2011; 32: 2326-32.
- Does cognitive reserve shape cognitive decline? Singh-Manoux A, Marmot MG, Glymour M, Sabia S, Kivimäki M, Dugravot A. Ann Neurol. 2011; 70: 296-304.
Whitehall II has collected an unrivalled set of multiple
repeat measures over 30 years of follow-up, complementing our
cardiovascular morbidity and mortality follow-up. For example, blood
pressure and body mass index have been measured on 6 occasions and oral
glucose tolerance on 4 occasions. Our longitudinal studies of diabetes
development have attracted much attention. The causes and consequences
of aortic stiffening is a novel focus of our cardiometabolic research,
which is also relevant to those interested in interventions to reduce
vascular ageing. Whitehall II is now collecting (2015) the third
measurement of carotid-femoral pulse wave velocity.
- Adiposity, Obesity, and Arterial Aging: Longitudinal Study of Aortic Stiffness in the Whitehall II Cohort. Brunner EJ, Shipley MJ, Ahmadi-Abhari S, Tabak AG, McEniery CM, Wilkinson IB, Marmot MG, Singh-Manoux A, Kivimaki M. Hypertension. 2015; 66(2): 294-300.
- Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study. Vistisen D, Witte DR, Tabák AG, Herder C, Brunner EJ, Kivimäki M, Færch K.PLoS Med. 2014; 11: e1001602.
- Prediabetes: a high-risk state for diabetes development. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Lancet. 2012;379: 2279-90.
- Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Hamer M, Sabia S, Batty GD, Shipley MJ, Tabák AG, Singh-Manoux A, Kivimaki M. Circulation. 2012; 126: 928-33.
- Arterial stiffness, physical function, and functional limitation: the Whitehall II Study. Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, Tabak AG, McEniery CM, Wilkinson IB, Kivimaki M. Hypertension. 2011; 57: 1003-9.
- Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. Kumari M, Shipley M, Stafford M, Kivimaki M. J Clin Endocrinol Metab. 2011; 96: 1478-85.
- Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. Wills AK, Lawlor DA, Matthews FE, Sayer AA, Bakra E, Ben-Shlomo Y, Benzeval M, Brunner E, Cooper R, Kivimaki M, Kuh D, Muniz-Terrera G, Hardy R. PLoS Med. 2011; 8:e1000440.
- Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Lancet. 2009; 373: 2215-21.
- Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, Miller M, Lowe GD, Rumley A, Casas JP, Shah T, Humphries SE, Hingorani AD, Marmot MG, Timpson NJ, Kumari M. PLoS Med. 2008; 5: e155.
- Dietary patterns and 15-y risks of major coronary events, diabetes, and mortality. Brunner EJ, Mosdøl A, Witte DR, Martikainen P, Stafford M, Shipley MJ, Marmot MG. Am J Clin Nutr. 2008 May; 87(5):1414-21.
A major aim of our research is to identify midlife risk
factors and protective factors for old-age functional limitations and
depression. In addition to social circumstances, lifestyle and chronic
diseases, we examine the role of biological factors, such as low-grade
inflammation, in predicting functioning and mental well-being at older
- Long-term inflammation increases risk of common mental disorder: a cohort study. Kivimäki M, Shipley MJ, Batty GD, Hamer M, Akbaraly TN, Kumari M, Jokela M, Virtanen M, Lowe GD, Ebmeier KP, Brunner EJ, Singh-Manoux A. Mol Psychiatry. 2014; 19: 149-50.
- Association of metabolically healthy obesity with depressive symptoms: pooled analysis of eight studies. Jokela M, Hamer M, Singh-Manoux A, Batty GD, Kivimäki M. Mol Psychiatry. 2014; 19: 910-4.
- Depression and type 2 diabetes: a causal association? Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Lancet Diabetes Endocrinol. 2014; 2: 236-45.
- Trajectories of the Framingham general cardiovascular risk profile in midlife and poor motor function later in life: the Whitehall II study. Elbaz A, Shipley MJ, Nabi H, Brunner EJ, Kivimaki M, Singh-Manoux A. Int J Cardiol. 2014; 172: 96-102.
- Cumulative associations between midlife health behaviors and physical functioning in early old age: a 17-year prospective cohort study. Sabia S, Elbaz A, Rouveau N, Brunner EJ, Kivimaki M, Singh-Manoux A. J Am Geriatr Soc. 2014; 62: 1860-8.
- Vascular risk status as a predictor of later-life depressive symptoms: a cohort study. Kivimäki M, Shipley MJ, Allan CL, Sexton CE, Jokela M, Virtanen M, Tiemeier H, Ebmeier KP, Singh-Manoux A. Biol Psychiatry. 2012; 72: 324-30.
- Common mental disorder and obesity: insight from four repeat measures over 19 years: prospective Whitehall II cohort study. Kivimäki M, Lawlor DA, Singh-Manoux A, Batty GD, Ferrie JE, Shipley MJ, Nabi H, Sabia S, Marmot MG, Jokela M. BMJ. 2009; 339: b3765.
Biological, environmental and lifestyle factors explaining
differences in health between people from different socioeconomic
circumstances have been a key research area for Whitehall II since the
beginning of the study. Our findings have had a strong impact on health
policy nationally and internationally. To understand the health effects
of workplace factors, such as work stress, we have combined data from
Whitehall II to those from other cohort studies.
- Association of lifecourse socioeconomic status with chronic inflammation and type 2 diabetes risk: the Whitehall II prospective cohort study. Stringhini S, Batty GD, Bovet P, Shipley MJ, Marmot MG, Kumari M, Tabak AG, Kivimäki M. PLoS Med. 2013; 10: e1001479.
- Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Kivimäki M, Nyberg ST, Batty GD, Fransson EI, Heikkilä K, Alfredsson L, Bjorner JB, Borritz M, Burr H, Casini A, Clays E, De Bacquer D, Dragano N, Ferrie JE, Geuskens GA, Goldberg M, Hamer M, Hooftman WE, Houtman IL, Joensuu M, Jokela M, Kittel F, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Kumari M, Madsen IE, Marmot MG, Nielsen ML, Nordin M, Oksanen T, Pentti J, Rugulies R, Salo P, Siegrist J, Singh-Manoux A, Suominen SB, Väänänen A, Vahtera J, Virtanen M, Westerholm PJ, Westerlund H, Zins M, Steptoe A, Theorell T; IPD-Work Consortium. Lancet. 2012; 380: 1491-7.
- Contribution of modifiable risk factors to social inequalities in type 2 diabetes: prospective Whitehall II cohort study. Stringhini S, Tabak AG, Akbaraly TN, Sabia S, Shipley MJ, Marmot MG, Brunner EJ, Batty GD, Bovet P, Kivimäki M. BMJ. 2012; 345: e5452.
- Stress and cardiovascular disease. Steptoe A, Kivimäki M. Nat Rev Cardiol. 2012; 9: 360-70.
- Association of socioeconomic position with health behaviors and mortality. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, Singh-Manoux A. JAMA. 2010; 303: 1159-66.
Page last modified on 23 jun 15 14:11